Clinical trial
Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for…
NCT00451217 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00451217 |
|---|---|
| Title | Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960) |
| Official title | A Multi -Center Randomized Parallel Group Comparative Active Controlled Safety Assessor Blinded Phase 3a Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agents of a Neuromuscular Block Induced by Rocuronium or Vecuronium at Reappearance of T2 |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anesthesia, General |
| Intervention type | Drug |
| Interventions | Sugammadex, Neostigmine |
| Enrollment | 198 |
| Start date | Nov 17, 2005 |
| Primary completion | Mar 6, 2006 |
| Completion | Mar 6, 2006 |
| First posted | Mar 23, 2007 |
| Last update posted | Mar 4, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: